FNBT
AGIO icon

FineMark National Bank & Trust’s Agios Pharmaceuticals AGIO Stock Holding History

FineMark National Bank & Trust’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-196
Closed -$8K – 1309
2016
Q2 		$8K Buy
+196
New +$9.68K ﹤0.01% 986

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

FineMark National Bank & Trust's AGIO Position: Q3 2016 in Review

FineMark National Bank & Trust sold out of Agios Pharmaceuticals (AGIO) in Q3 2016, closing a stake of 196 shares — an estimated $8K sold.

FineMark National Bank & Trust first reported a position in AGIO in Q2 2016 and held it in 1 quarter. The position peaked at $8K in Q2 2016. 163 funds tracked by Wall St. Rank hold AGIO as of Q3 2016.

  • FineMark National Bank & Trust reported no remaining Agios Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • FineMark National Bank & Trust sold 196 Agios Pharmaceuticals shares in Q3 2016, an estimated $8K.
  • FineMark National Bank & Trust first reported a position in Agios Pharmaceuticals in Q2 2016 and held it in 1 quarter.
  • FineMark National Bank & Trust's Agios Pharmaceuticals position peaked at $8K in Q2 2016.
  • 163 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2016.

Based on FineMark National Bank & Trust's 13F filing for Q3 2016, filed 10 Nov 2016.